title: How Hyperprolactinemia Affects Sexual Function in Patients Under Antipsychotic Treatment.
abstract: OBJECTIVE
  We aimed to study the relationship between hyperprolactinemia (HPRL) and sexual dysfunction (SED) in a sample of patients being prescribed a dose-stable antipsychotic medication, and to evaluate sex differences in the prevalence of HPRL and SED and their relationship.
  
  
  METHODS
  A cross-sectional study was carried out including patients between 18 and 55 years of age with a psychotic spectrum diagnosis who were attending community mental health services or hospitalized in medium and long stay units. Positive and Negative Syndrome scale, Calgary depression scale for schizophrenia, Personal and Social Performance scale, and Changes in Sexual Functioning questionnaire-short form were administered. Not later than 3 months, a determination of prolactin, follicle-stimulating hormone, luteinizing hormone, estrogen (only in women) and testosterone was performed.
  
  
  RESULTS
  A final sample of 101 patients (30 women and 71 men) was recruited. Seventy-two patients (71.3%) showed HPRL. Sexual dysfunction was significantly higher in HPRL patients than in non-HPRL patients (79.17% vs 51.72%) (P = 0.006), and mean prolactin values were significantly higher in case of SED (P = 0.020). No sex differences were found in prevalence of HPRL or SED. Low Personal and Social Performance scale scores and HPRL were factors independently associated with SED, whereas alcohol use was an independent protector factor.
  
  
  CONCLUSIONS
  In our study, SED was significantly related to HPRL without showing sex differences. Prevalence of HPRL and SED observed was higher than that in previous studies, which should be taken into consideration because these have been associated with higher morbimortality, and noncompliance and relapse, respectively.
authors.affiliation: From the *Research and Development Unit, †Endocrinology Department, and ‡Radiology Department, Parc Sanitari Sant Joan de Déu, Universitat de Barcelona (UB), Sant Boi de Llobregat, Barcelona, Spain; §Psychiatry Department, Braulio A. Moyano Neuropsychiatric Hospital, Buenos Aires, Argentina.
authors.forename: Elena
authors.initials: E
authors.lastname: Rubio-Abadal
authors.forename: Núria
authors.initials: N
authors.lastname: Del Cacho
authors.forename: Gerard
authors.initials: G
authors.lastname: Saenz-Navarrete
authors.forename: Belen
authors.initials: B
authors.lastname: Arranz
authors.forename: Rosa-Maria
authors.initials: RM
authors.lastname: Cambra
authors.forename: Daniel
authors.initials: D
authors.lastname: Cuadras
authors.forename: Demián
authors.initials: D
authors.lastname: Rodante
authors.forename: Csaba
authors.initials: C
authors.lastname: Fehér
authors.forename: Mercedes
authors.initials: M
authors.lastname: Roca
authors.forename: Vanessa
authors.initials: V
authors.lastname: Barneda
authors.forename: Judith
authors.initials: J
authors.lastname: Usall
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000097:blood / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D011618:Psychotic Disorders / Q000188:drug therapy*; D012735:Sexual Dysfunction, Physiological / Q000139:chemically induced*
chemical_list: D014150:Antipsychotic Agents